Iterum Therapeutics Set to Shine at the Upcoming Summit
Iterum Therapeutics at the Maxim Healthcare Virtual Summit
Iterum Therapeutics plc (ITRM) is gearing up to participate in the very important Maxim Healthcare Virtual Summit. This clinical-stage pharmaceutical company is renowned for its focus on developing next-generation oral antibiotics designed to tackle infections that arise from multi-drug resistant bacteria, particularly in community settings. Corey Fishman, the CEO of Iterum, is set to have an engaging Fireside Chat with Jason McCarthy, Ph.D., a well-respected figure in biotechnology research at Maxim Group. This chat will take place at 10:00 a.m. ET.
Details on the Summit
The Maxim Healthcare Summit is scheduled to run from October 15 to 17, featuring a dynamic array of discussions related to the healthcare industry. Attendees will gain insights into key topics affecting the market, along with the latest developments in the treatment of infectious diseases. Thanks to M-Vest, the conversations will be accessible online, allowing for extensive participation and viewership.
About Iterum Therapeutics
Iterum Therapeutics is dedicated to advancing its mission of addressing the urgent global crisis posed by multi-drug resistant pathogens. The company is devoted to enhancing the quality of life for those afflicted by serious health issues globally. Iterum's most promising product, sulopenem, represents a novel approach as a penem anti-infective compound, available in both oral and IV forms. This compound boasts impressive in vitro activity against a spectrum of bacteria, including numerous gram-negative and gram-positive strains resistant to various antibiotics.
Regulatory Advancements
One of the significant milestones for Iterum Therapeutics includes the submission of a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women. The U.S. Food and Drug Administration has accepted this NDA for review. This process highlights the importance of Iterum's work in the field, which has also garnered Qualified Infectious Disease Product (QIDP) and Fast Track designations for several uses of sulopenem.
Contact Information for Investors
For investors interested in the latest developments or potential opportunities with Iterum Therapeutics, they can reach out to Judy Matthews, the Chief Financial Officer, at 312-778-6073. Investors can also connect via email at IR@iterumtx.com.
Frequently Asked Questions
What is the focus of Iterum Therapeutics?
Iterum Therapeutics focuses on developing novel antibiotics to combat multi-drug resistant infections.
When will the Maxim Healthcare Virtual Summit take place?
The summit is scheduled from October 15 – 17, 2024.
Who will be featured in the Fireside Chat?
The Fireside Chat will feature Corey Fishman and Dr. Jason McCarthy discussing critical issues in biotechnology.
What is the significance of sulopenem?
Sulopenem is potential treatment for common urinary tract infections, offering a new option against resistant bacteria.
How can investors learn more about Iterum?
Investors can reach out to the company through their Investor Relations contact or visit their website for updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Florida's Cannabis Legalization: Inside the Campaign Strategies
- Pluribus Technologies Enhances Forbearance Agreement to Support Growth
- Pluribus Technologies Enhances Agreement with National Bank
- Understanding the Impact of U.S. Elections on Bitcoin Markets
- Market Insights: Fed Minutes Anticipated as Rates Hover
- Innovative System-in-Package Solutions by Lantronix for AI/ML at the Edge
- ThreeD Capital Inc. Reports September 2024 Net Asset Value Insights
- Why Rapid Hurricane Intensification is a Growing Concern Now
- James Aitken Takes the Lead at Northpoint Recovery Holdings
- Massive Consumer Victory on Credit Report Violations Achieved
Recent Articles
- HPH Board Sees Renewed Leadership with New Appointments
- Banana Flour Market Thrives with AI Innovations and Growth Trends
- Investigating Vanda Pharmaceuticals: A Closer Look at the Issues
- Fanhua Inc. Welcomes New Board Leadership in Major Advancement
- Investigation Into Napco Security Technologies Raises Concern
- Investors Mobilize as Kaspi.kz Faces Securities Fraud Claims
- Investigation into Caleres, Inc. Due to Investor Claims
- Investigation into VinFast Auto Ltd. Reveals Financial Losses
- Revance Therapeutics: Investigating Possible Securities Fraud
- Visa Inc. Faces Antitrust Challenges Amid Shareholder Concerns
- Investigation of 2seventy bio, Inc. Sparks Investor Interest
- Investigation Concerning Winnebago Industries Inc. - WGO
- Investigation Underway for Laser Photonics Corporation Investors
- Investigation Launched Into Torrid Holdings Inc. with CURV Ticker
- CBORD Secures StateRAMP Authorization to Enhance Security Standards
- Investigation Launches for JFrog Ltd. Following Concerns
- Mizuho Stays Positive on Diamondback Energy's Growth Potential
- Deutsche Bank Lowers Walgreens Target: An In-Depth Analysis
- Illumina's New MiSeq i100 System and Market Outlook
- MtronPTI Welcomes New CFO Cameron Pforr Amid Strong Growth
- Procter & Gamble's Growth Forecast: Analysts Weigh In
- Vaccinex Faces Nasdaq Challenges Amid Financial Hurdles
- eHealth Boosts Leadership Stability with New Executive Incentives
- Core & Main's Strategic Acquisition Enhances Fire Protection Offerings
- Banc of California Executive Changes Amid Financial Trends
- Stock Movement Insights: 10x Genomics, AZZ, and Applied Digital
- Key Updates on Class Action Against iLearningEngines, Inc.
- GSK Options Trading Unveils Market Trends and Insights
- Insightful Strategies in Walt Disney's Options Trading
- Understanding the Recent Options Activity in NCLH Trading
- Daren Bascome Encourages Designers to Embrace Connection
- Indonesia Energy Corp Sees 11.39% Rise in Short Interest
- Cameron Pforr Joins M-tron Industries as CFO to Drive Growth
- General Motors Pricing Strategies Impact Market Dynamics
- QuantumScape to Share Q3 2024 Results: Key Details Inside
- Americas Gold and Silver Boosts Private Placement to C$45 Million
- FHLB Dallas and Austin Bank's Generous Grant for Tribal Housing
- AZZ Inc. Achieves Significant Growth in Q2 Fiscal Year 2025
- Cohen & Steers Preparing for Q3 2024 Earnings Release
- Jack McInerney Joins BTY Ownership Group, Promises Innovation
- Carpenter Technology Corporation Elects Directors and Plans Growth
- Miami International Holdings Champions Financial Literacy Initiatives
- Aditxt Navigates Nasdaq Challenges Amid Strategic Growth Plans
- INdigital's Emergency Response Team Gears Up for Hurricane Season
- Miami International Holdings Celebrates Financial Literacy Efforts
- Pfizer Declares Strong Quarterly Dividend and Highlights Growth
- Cboe Enhances Market Strategies with New VIX Options Launch
- Illumina's New MiSeq i100 Series: A Game Changer for Genomics
- Ocular Therapeutix Enhances Employee Stock Incentive Scheme
- Western Acquisition Ventures Corp. Strengthens Investor Relations